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Drug-Eluting Stenting Followed
by Cilostazol Treatment Reduces Late
Restenosis in Patients With Diabetes Mellitus
The DECLARE-DIABETES Trial (A Randomized
Comparison of Triple Antiplatelet Therapy With Dual Antiplatelet
Therapy After Drug-Eluting Stent Implantation in Diabetic Patients)
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Jae-Hyeong Park, MD, PHD,‡ Jae-Hwan Lee, MD,‡ Si Wan Choi, MD,‡
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June Hong Kim, MD, PHD, Kook-Jin Chun, MD, Seung-Jung Park, MD, PHD, FACC*
Seoul, Jeonju, Daejeon, Bucheon, and Busan, Korea
Objectives We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implan-
tation in patients with diabetes mellitus (DM).
Background Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal
stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients.
Methods This randomized, multicenter, prospective study compared triple antiplatelet therapy (aspirin, clopidogrel, and
cilostazol, triple group, n  200) and dual antiplatelet therapy (aspirin and clopidogrel, standard group, n 
200) for 6 months in patients with DM receiving DES. The primary end point was in-stent late loss at 6 months.
Results The 2 groups had similar baseline clinical and angiographic characteristics. The in-stent (0.25  0.53 mm vs.
0.38  0.54 mm, p  0.025) and in-segment (0.42  0.50 mm vs. 0.53  0.49 mm, p  0.031) late loss were
significantly lower in the triple versus standard group, as were 6-month in-segment restenosis (8.0% vs. 15.6%,
p  0.033) and 9-month target lesion revascularization (TLR) (2.5% vs. 7.0%, p  0.034). At 9 months, major
adverse cardiac events, including death, myocardial infarction, and TLR, tended to be lower in the triple than in
the standard group (3.0% vs. 7.0%, p  0.066). Multivariate analysis showed that sirolimus-eluting stents and
the use of cilostazol were strong predictors of reduced restenosis or TLR.
Conclusions Triple antiplatelet therapy after DES implantation decreased angiographic restenosis and extent of late loss, re-
sulting in a reduced risk of 9-month TLR compared with dual antiplatelet therapy in diabetic patients. (J Am
Coll Cardiol 2008;51:1181–7) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.049m
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eointimal hyperplasia and restenosis compared with bare-
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007, accepted November 13, 2007.etal stents (BMS) in patients with diabetes mellitus (1),
iabetes mellitus remians a strong predictor of restenosis with
ES (2). Cilostazol, a phosphodiesterase III inhibitor, has
ntiproliferative effects, as shown by its reduction of intimal
yperplasia and restenosis in patients after BMS implantation
3). The impact of cilostazol on neointimal hyperplasia after
ES implantation, however, has not been evaluated in diabetic
atients. Therefore, we performed a prospective, randomized,
ulticenter study comparing triple (aspirin, clopidogrel, and
ilostazol) and dual antiplatelet therapy (aspirin and clopi-
ogrel) for 6 months in diabetic patients undergoing DES.
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Patient selection. This study
included 400 diabetic patients
18 years of age with angina
pectoris or positive stress test and
a native coronary lesion (diameter
stenosis 50% and reference di-
ameter 2.5 mm). The study
involved 5 centers in Korea be-
tween May 2005 and March
2006. Patients were excluded if
they had contraindication to as-
pirin, clopidogrel, or cilostazol; left
main disease; graft vessel disease;
left ventricular ejection fraction
30%; leukocyte count 3,000/
mm3 and/or platelet count
100,000/mm3; asparatate ami-
otransferase or alanine aminotransferase 3 times upper
ormal; serum creatinine2.0 mg/dl; noncardiac disease with
life expectancy 1 year; planned bifurcation stenting; pri-
ary angioplasty for acute myocardial infarction (MI) within
4 h; or inability to follow the protocol. In patients with
ultiple lesions, the first stented lesion was considered as
arget lesion. The institutional review board at each partic-
pating center approved the protocol. All patients provided
ritten informed consent.
andomization and procedures. Once the guidewire
rossed the lesion, patients were randomly assigned to
irolimus-eluting stents (SES) or paclitaxel-eluting stents
PES). After DES randomization, patients randomly were
llocated to triple (aspirin, clopidogrel, and cilostazol, triple
roup, n  200) or dual antiplatelet therapy (aspirin and
lopidogrel, standard group, n  200) on the basis of a
-by-2 factorial design using sealed envelopes containing a
omputer-generated randomization sequence. Beginning at
east 24 h before the procedure, all patients received aspirin
200 mg daily) and clopidogrel (300 mg loading dose, 75 mg
aily for at least 6 months). Patients in the triple group
eceived 200 mg of cilostazol (loading dose) immediately
fter the procedure, followed by 100 mg twice daily for 6
onths. Coronary stenting was performed according to the
tandard technique. The decision of predilation or direct
tenting was made by the operator, as was the use of
lycoprotein IIb/IIIa inhibitors.
tudy end point and definitions. The primary end point
as in-stent late loss at 6 months. The secondary end points
ncluded in-segment late loss and restenosis rate (diameter
tenosis 50%) at 6 months, stent thrombosis, target vessel
evascularization (TVR), and major adverse cardiac events
MACE), including death, MI, and target lesion revascu-
arization (TLR) at 9 months. Safety assessments included
ajor bleeding (a need for transfusion, a reduction in
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MACE  major adverse
cardiac events
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
QCA  quantitative
coronary angiography
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationemoglobin of 5 g/dl, need for surgical intervention, or esulting in hypotension requiring inotropic support), minor
leeding, any adverse reactions (neutropenia 1.5  109/l,
hrombocytopenia 100  109/l, skin rash, liver dysfunc-
ion, and gastrointestinal trouble), and incidence of drug
iscontinuation during treatment period.
Angiographic success was defined as in-segment diameter
tenosis 30% by the use of quantitative coronary angiog-
aphy (QCA). Myocardial infarction was defined as a
reatine kinase myocardial band 3 times the upper normal
imit. Target lesion revascularization was considered clini-
ally driven if prompted by symptoms or signs consistent
ith myocardial ischemia or if lesion diameter stenosis was
ore than 70% at follow-up. Stent thrombosis was defined
s any of the following: angiographic documentation of
tent occlusion with or without the presence of thrombus
ssociated with an acute ischemic event, unexplained
udden death, and MI not clearly attributable to another
oronary lesion.
ollow-up. Repeat coronary angiography was performed at
months, or earlier if indicated. Clinical follow-up visits
ere scheduled at 30, 90, 180, and 270 days. Drug compli-
nce was assessed using a compliance questionnaire. Figure
shows the flow of patients during follow-up. All adverse
linical events were assessed by an independent events
ommittee that was blinded to treatment groups.
CA analysis. Pre-procedure, post-procedure, and follow-up
ngiograms obtained after intracoronary nitroglycerin admin-
stration were submitted to the core analysis center (Asan
edical Center, Seoul, Korea), in which the intraobserver and
nterobserver correlation coefficients were 0.92 and 0.93. Dig-
tal angiograms were analyzed using an automated edge detec-
ion system (CASS II, Pie Medical, Maastricht, the Nether-
ands). Quantitative coronary angiography measurements were
btained for both in-stent and in-segment (stented segment
nd margins 5 mm proximal and distal to stent). In-segment
ate loss was calculated using maximal regional late loss method
4). Patterns of restenosis were assessed using the Mehran
lassification (5).
tatistical analysis. On the basis of our registry (6), we
ssumed a mean (SD) in-stent late loss of 0.39  0.45
m in the dual antiplatelet group. Calculation of sample
ize was based on an equivalent margin for in-stent late loss
f 0.16 mm, 2-sided alpha level of 0.05, and 90% power.
otal sample size was estimated to be 400 patients (200
atients per group) on the expectation of 20% loss for
ngiographic follow-up. Analyses of 2 groups were per-
ormed according to the intention-to-treat principle. Con-
inuous variables are presented as mean  SD and com-
ared with the use of Student unpaired t tests. Categorical
ariables are presented as numbers or percentages and were
ompared with chi-square or Fisher exact tests. To assess
ossible interaction of DES effect for outcome measures, we
sed multiple linear or logistic regression analysis. A p value
0.05 was considered statistically significant.
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aseline characteristics. There were no significant differ-
nces between groups in baseline clinical characteristics
Table 1).
n-hospital outcomes. The 2 groups had similar proce-
ural characteristics (Table 2). The angiographic success rate
as 99.5% in both groups. Acute stent thrombosis developed
n 1 patient in the standard group during hospitalization.
n-hospital events, including Q-wave MI, emergency bypass
urgery, and death, did not occur in either group.
ngiographic outcomes. The 2 groups had similar base-
ine and post-procedural QCA characteristics except for
igher post-procedural in-stent diameter stenosis in the
riple group (Table 3). Follow-up angiography was per-
ormed in 81.5% of the triple group and 83.5% of
Figure 1 Study Flow During Follow-Up Period
After drug-eluting stent randomization, patients were randomly allocated in a 1:1 r
the dual antiplatelet therapy group (aspirin and clopidogrel; standard group) on the
comes were assessed.he standard group (p  0.599). At 6 months, in-stent t0.25  0.53 mm vs. 0.38  0.54 mm, p  0.025) and
n-segment (0.42  0.50 mm vs. 0.53  0.49 mm, p 
.031) late loss were significantly lower in the triple
ersus standard group (Table 3). However, the peristent
in-segment  in-stent) late loss was not different
etween the 2 groups (0.17  0.29 mm in the triple
roup vs. 0.15  0.27 mm, p  0.663). The in-stent (p
0.096) and in-segment minimum lumen diameters
p  0.046) were larger in the triple versus standard
roup. On multivariate analysis, DES interaction was not
ignificant (in-stent late loss: p  0.827, in-segment late
oss: p  0.428). However, the DES effect was signifi-
ant. The in-stent (0.13  0.43 mm vs. 0.53  0.57 mm,
 0.001) and in-segment (0.31 0.40 mm vs. 0.67 0.53
m, p 0.001) late loss were significantly lower in the SES
the triple antiplatelet group (aspirin, clopidogrel, and cilostazol; triple group) or
of a 2-by-2 factorial design. Six-month angiographic and 9-month clinical out-atio to
basishan in PES group.
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Cilostazol After Drug-Eluting Stenting March 25, 2008:1181–7There was a trend toward lower in-stent restenosis (7.4%
s. 13.2%, p  0.083), but in-segment restenosis (8.0% vs.
5.6%; relative risk 0.51; 95% confidence interval 0.27 to
.96; p  0.033) was lower in the triple versus standard
roup. In patients with restenoses, there were similar
atterns of focal and diffuse restenosis in the 2 groups
Table 4). On multivariate analysis, DES interaction effect
as significant (in-stent restenosis: p  0.001, in-segment
estenosis: p  0.001). In SES, the angiographic restenosis
or in-stent (0% vs. 6.8%, p 0.03) and in-segment (0% vs.
.0%, p  0.014) were statistically different in both groups.
n PES, the angiographic restenosis for in-stent (16.0% vs.
0.3%, p  0.494) and in-segment (17.3% vs. 24.1%, p 
.304) was not different in both groups. In subgroup
nalysis, triple therapy in SES had significantly lower
n-segment restenosis (0%, 0 of 88) than standard therapy in
Baseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
Variable
Age, yrs
Men
Hypertension
Treatment of diabetes mellitus
Dietary therapy alone
Oral hypoglycemic agent
Insulin
Glycosylated hemoglobin
Total cholesterol 200 mg/dl
Current smoker
Previous percutaneous coronary intervention
Previous coronary artery bypass surgery
Clinical diagnosis
Stable angina
Unstable angina
Acute myocardial infarction
Left ventricular ejection fraction, %
Multivessel disease
Angiographic Characteristics and Procedural Re
Table 2 Angiographic Characteristics and P
Variable
SES/PES
Target vessel
Left anterior descending artery 1
Left circumflex artery
Right coronary artery
Maximal inflation pressure, atm 1
Use of intravascular ultrasound
Use of glycoprotein IIb/IIIa inhibitor
Predilation before stenting 1
Multivessel stenting
Number of used stents at the target lesion 1
Procedure-related non–Q-wave MIMI  myocardial infarction; PES  paclitaxel-eluting stent; SES  sirolimus-eES (8%, 7 of 88, p  0.014), triple therapy in PES (17.3%
3 of 75, p  0.001), and standard therapy in PES (24.1%,
9 of 79, p  0.001).
On a per-protocol basis, triple therapy had a smaller
n-stent (0.25  0.55 mm vs. 0.39  0.54 mm, p  0.032)
nd in-segment late loss (0.41  0.50 mm vs. 0.53  0.49
m, p 0.026). Angiographic restenosis for in-stent (7.7% vs.
3.5%, p  0.107) and in-segment (8.5% vs. 16.0%, p 
.048) was lower in the triple group versus the standard group.
linical outcomes. A 9-month follow-up was performed in
ll patients (Table 5). One fatal nontarget vessel acute MI
ccurred at 6 months in the triple group. Target lesion
evascularization was significantly lower in the triple versus the
tandard group (2.5% vs. 7.0%; relative risk 0.36; 95% confi-
ence interval 0.13 to 0.97; p  0.034). However, TVR did
ot differ significantly (3.5% vs. 8.0%, p  0.075). Clinically
iple
200)
Standard
(n  200) p Value
8.5 60.7  9.1 0.704
59.0%) 114 (57.0%) 0.685
59.5%) 119 (59.5%) 0.999
0.591
10.0%) 17 (8.5%)
75.5%) 147 (73.5%)
14.5%) 36 (18.0%)
1.9% 7.6  1.6% 0.237
30.5%) 57 (28.5%) 0.661
24.0%) 63 (31.5%) 0.094
12.0%) 26 (13.0%) 0.762
1.0%) 5 (2.5%) 0.449
0.861
41.5%) 85 (42.5%)
38.0%) 71 (35.5%)
20.5%) 44 (22.0%)
10 58  10 0.357
65.5%) 125 (62.5%) 0.532
ural Results
le
00)
Standard
(n  200) p Value
100 100/100
0.333
3.0%) 114 (57.0)
3.5%) 26 (13.0%)
3.5%) 60 (30.0%)
3.8 14.8  3.4 0.321
2.5%) 66 (33.0%) 0.915
.0%) 10 (5.0%) 0.630
5.5%) 193 (96.5%) 0.450
6.5%) 60 (30.0%) 0.168
0.59 1.27  0.51 0.587
0.0%) 14 (7.0%) 0.282Tr
(n 
61.0 
118 (
119 (
20 (
151 (
29 (
7.8 
61 (
48 (
24 (
2 (
83 (
76 (
41 (
59 sults
roced
Trip
(n  2
100/
26 (6
27 (1
47 (2
5.2 
65 (3
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91 (9
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20 (1luting stent.
d
6
s
t
0
P
t
p
a
d
c
m
a
i
A
i
g
a
s
t
d
D
T
t
a
r
o
i
s
4%)
A
*
1185JACC Vol. 51, No. 12, 2008 Lee et al.
March 25, 2008:1181–7 Cilostazol After Drug-Eluting Stentingriven TLR (2.0% vs. 6.0%, p  0.041) and TVR (3.0% vs.
.5%, p  0.100) rates were lower in the triple versus the
tandard group. At 9 months, MACE tended to be lower in
he triple than in the standard group (3.0% vs. 7.0%, p 
.066).
redictors of restenosis and clinical outcomes. On mul-
ivariate analysis, all clinical and angiographic variables with
 0.2 in univariate analysis and known predictors of
ngiographic restenosis (7) were tested. Independent pre-
Quantitative Angiographic Measurements
Table 3 Quantitative Angiographic Measure
Variable
Tripl
(n  2
Angiographic follow-up, % 163 (8
Reference diameter, mm 2.81
Lesion length, mm 26.7
Stented length, mm 33.5
Minimum lumen diameter, mm
In-segment
Before procedure 0.79
After procedure 2.24
At follow-up 2.15
In-stent
After procedure 2.55
At follow-up 2.32
Diameter stenosis, %
In-segment
Before procedure 68.4
After procedure 20.6
At follow-up 24.6
In-stent
After procedure 11.1
At follow-up 18.5
Acute gain, mm
In-segment 1.44
In-stent 1.75
Late loss, mm
In-segment 0.42
In-stent 0.25
Binary angiographic restenosis
In-segment 13 (8.
In-stent 12 (7.
ngiographic Patterns of Restenosis*
Table 4 Angiographic Patterns of Restenosis*
Variable
Triple
(n  13)
Standard
(n  26) p Value
Focal 8 (61.5%) 16 (61.5%) 0.999
IA (articulation or
gap)
0 0
IB (margin) 2 4
IC (focal body) 4 8
ID (multifocal) 2 4
Diffuse 5 (38.5%) 10 (38.5%) 0.999
II (intrastent) 3 8
III (proliferative) 1 2
IV (total occlusion) 1 0lClassified with the Mehran criteria (5).ictors of angiographic restenosis were SES, the use of
ilostazol, lesion length, and post-procedural minimal lu-
en diameter. Independent predictors of TLR were SES
nd the use of cilostazol. However, SES was the only
ndependent predictor of MACE (Table 6).
dverse drug effects. No patient experienced major bleed-
ng (Table 7). Skin rash was more common in the triple
roup (p  0.036). Drug discontinuation for adverse events
nd other reasons was more common in the triple versus the
tandard group (p  0.001). The most common reasons for
ermination of cilostazol were skin rash and gastrointestinal
isturbance.
iscussion
he major finding in this study is that triple antiplatelet
herapy for 6 months, compared with standard therapy, is
ssociated with reduction of late loss and angiographic
estenosis after DES implantation in diabetic patients with-
ut increased risk of serious adverse effects. This translates
nto a reduced risk of 9-month TLR.
A previous study has shown that cilostazol inhibited
tent-induced P-selectin expression on platelets and upregu-
s
Standard
(n  200) p Value
167 (83.5) 0.599
2.78 0.46 0.505
26.3 13.8 0.806
32.1 13.9 0.348
0.73 0.49 0.170
2.24 0.49 0.930
2.03 0.58 0.046
2.57 0.44 0.548
2.20 0.63 0.096
69.0 14.2 0.708
18.8 11.2 0.135
27.7 16.7 0.081
8.3 11.8 0.034
20.9 20.5 0.244
1.51 0.63 0.218
1.84 0.61 0.109
0.53 0.49 0.031
0.38 0.54 0.025
26 (15.6%) 0.033
22 (13.2%) 0.083ment
e
00)
1.5)
0.40
13.3
15.2
0.47
0.44
0.55
0.42
0.59
13.5
11.2
15.6
11.2
18.7
0.55
0.56
0.50
0.53
0%)ation of leukocyte Mac-1, which is associated with inhibi-
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Cilostazol After Drug-Eluting Stenting March 25, 2008:1181–7ion of neointimal hyperplasia and restenosis after stent
mplantation (8). Another mechanism of cilostazol action is
hrough upregulation of antioncogenes p53 and p21, and
epatocyte growth factor in vascular smooth muscle cells
fter vessel injury (9). These mechanisms are associated with
he reduction in late loss observed in this study.
We found that triple therapy significantly reduced in-
tent late loss, a surrogate of neointimal hyperplasia. The
n-stent late loss is a more reliable measurement than
estenosis rate in discriminating efficacy of DES (10). A
redictive model has demonstrated that greater late loss is
ssociated with greater angiographic restenosis (11). In our
tudy, in-stent late loss, which was 0.38  0.54 mm in the
tandard group, was reduced to 0.25  0.53 mm in the
riple group (p  0.05), and in-segment late loss was
educed from 0.53  0.49 mm to 0.42  0.50 mm,
espectively (p  0.05). Late loss was smaller in patients
linical Outcomes at 9 Months
Table 5 Clinical Outcomes at 9 Months
Variable
Triple
(n  200)
Standard
(n  200) p Value
Death 1 (0.5%) 0 0.999
Cardiac 1 (0.5%) 0
Noncardiac 0 0
MI 1 (0.5%) 1 (0.5%) 0.999
Q-wave 1 (0.5%) 0
Non–Q-wave 0 1 (0.5%)
TLR 5 (2.5%) 14 (7.0%) 0.034
Drug-eluting stent 1 (0.5%) 10 (5%)
Cutting balloon 2 (1%) 2 (1%)
Bypass surgery 2 (1%) 2 (1%)
Stent thrombosis 0 1 (0.5%) 0.999
Acute 0 1 (0.5%)
Subacute 0 0
Late 0 0
TVR 7 (3.5%) 16 (8.0%) 0.053
Death/MI/TVR 8 (4.0%) 16 (8.0%) 0.092
MACE 6 (3.0%) 14 (7.0%) 0.066
ACE  major adverse cardiac events including death, myocardial infarction, and target lesion
evascularization; MI  myocardial infarction; TLR  target lesion revascularization; TVR  target
essel revascularization.
redictors of Angiographic Restenosisnd Clinical Outcomes on Multivariate Analysis
Table 6 Predictors of Angiographic Restenosisand Clinical Outcomes on Multivariate Analysis
Odds
Ratio
95% Confidence
Interval p Value
Angiographic restenosis
Sirolimus-eluting stent 0.15 0.06–0.40 0.0001
Cilostazol 0.32 0.11–0.89 0.029
Lesion length 1.03 1.01–1.06 0.013
Post-procedural MLD 0.17 0.05–0.28 0.005
Target lesion revascularization
Sirolimus-eluting stent 0.24 0.07–0.81 0.021
Cilostazol 0.26 0.07–0.95 0.042
Major adverse cardiac events
Sirolimus-eluting stent 0.21 0.06–0.71 0.012fLD  minimal lumen diameter.ssigned to triple therapy, whether implanted with SES or
ES. Thus, cilostazol treatment for 6 months may improve
fficacy of DES, in terms of angiographic and clinical
utcomes.
In-stent late loss has been positively correlated with
LR and angiographic restenosis (4,11). We found that
he triple group had significantly lower in-stent and
n-segment late loss, resulting in significant reductions in
LR and angiographic restenosis. The relative risk re-
uctions of restenosis and TLR in the triple group were
8.8% and 64.3%, respectively. The magnitude of relative
isk reduction of restenosis by triple therapy was compa-
able with the reduction (53%) found by the CREST
Cilostazol for RESTenosis trial) investigators (3), in
hich researchers evaluated the effect of cilostazol after
MS implantation. Interestingly, in the current study,
he impact of cilostazol appeared more prominent in SES
han PES in reducing angiographic restenosis. Moreover,
ES plus triple treatment reduced restenosis more than
ES plus standard treatment or PES plus either triple or
tandard treatment. These results were supported by multi-
ariate analysis showing that SES and cilostazol treatment
ere predictors of lack of restenosis and TLR. However, the
ynergistic potential of SES with cilostazol requires the further
tudy.
The triple group had a greater rate of drug discontinua-
ion than the standard group, but there were no episodes of
ajor bleeding in either group. Moreover, significant ad-
erse drug events were not detected in the triple group,
uggesting that the triple antiplatelet regimen can be safely
pplied for 6 months.
tudy limitations. The present study has several limita-
ions. First, despite its prospective, randomized design, this
tudy was open label. To compensate for this limitation,
ore laboratory QCA analysis and assessment of outcomes
ere performed in a blinded manner. Second, there might
e a possible bias associated with clinical decisions related to
LR. Finally, routine 6-month angiographic follow-up may
ave resulted in an underestimation of restenosis rate, late
oss, and TLR when compared with a longer angiographic
dverse Drug Effects
Table 7 Adverse Drug Effects
Variable
Triple
(n  200)
Standard
(n  200) p Value
Bleeding 3 (1.5%) 3 (1.5%) 0.999
Major bleeding 0 0
Minor bleeding 3 (1.5%) 3 (1.5%)
Rash 15 (7.5%) 5 (2.5%) 0.036
Gastrointestinal trouble 9 (4.5%) 5 (2.5%) 0.416
Thrombocytopenia 0 1 (0.5%) 0.999
Neutropenia 0 0 0.999
Hepatic dysfunction 2 (1.0%) 1 (0.5%) 0.999
Drug discontinuation 29 (14.5%) 5 (2.5%) 0.001ollow-up period.
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n conclusion, triple antiplatelet therapy after DES implan-
ation resulted in a significantly smaller late loss and
ecreased angiographic restenosis and TLR compared with
tandard antiplatelet therapy in diabetic patients.
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